High Tower Advisors, LLC Cybin Inc. Transaction History

High Tower Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.26 - $0.46 $21,157 - $37,432	-81,375 Reduced 84.6%	14,808 $3,000
Q1 2024 May 06, 2024	BUY	$0.3 - $0.46 $14,275 - $21,888	47,584 Added 97.91%	96,183 $39,000
Q4 2023 Feb 12, 2024	BUY	$0.38 - $0.65 $13,490 - $23,075	35,500 Added 271.01%	48,599 $19,000
Q3 2023 Nov 08, 2023	BUY	$0.29 - $0.63 $28 - $63	100 Added 0.77%	13,099 $6,000
Q1 2023 May 11, 2023	SELL	$0.3 - $0.56 $3,600 - $6,720	-12,000 Reduced 48.0%	12,999 $4,000
Q4 2022 Feb 08, 2023	BUY	$0.26 - $0.64 $630 - $1,552	2,425 Added 10.74%	24,999 $7,000
Q3 2022 Nov 09, 2022	SELL	$0.48 - $1.11 $8,364 - $19,342	-17,426 Reduced 43.57%	22,574 $11,000
Q2 2022 Aug 10, 2022	BUY	$0.41 - $0.88 $1,564 - $3,357	3,815 Added 10.54%	40,000 $23,000
Q1 2022 May 12, 2022	SELL	$0.74 - $1.22 $8,880 - $14,640	-12,000 Reduced 24.9%	36,185 $29,000
Q4 2021 Feb 10, 2022	BUY	$1.13 - $2.31 $54,449 - $111,307	48,185 New	48,185 $57,000

66.1K

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $1.58B
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.